| 1. |
［1］Gao JP, Dong J, Cai W, Hong BF, Wang XX, Li YT.Actuality of maximum androgen blockade in prostate cancer[J]. Journal of clinical urology, 2002; 17(6): 314-316.
|
| 2. |
高江平,董雋,蔡偉,洪寶發,王曉雄,李炎唐雄激素最大限度阻斷治療前列腺癌的現狀[J].臨床泌尿外科雜志,2002;17(6):314-316.
|
| 3. |
［2］Fu WJ. Progress of discontinuous androgen blockade in prostate cancer[J]. Urinary system fascicule of foreign medical sciences,2002:22(5):287-289.
|
| 4. |
符偉軍.間斷性雄激素阻斷治療前列腺癌的研究進展[J].國外醫學泌尿系統分冊,2002;22(5):287-289.
|
| 5. |
［3］Bono AV, Pagano F, Montironi R, Zattoni F, Manganelli A, Selvaggi FP, Comeri G, Fiaccavento G, Guazzieri S, Selli C, Lembo A, Cosciani-Cunico S, Potenzoni D, Muto G,Diamanti L, Santinelli A, Mazzucchelli R, Prayer-Galletti T;Italian PROSIT Study Group. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study[J ]. Urology, 2001 ;57 (1): 117-21.
|
| 6. |
［4］Prostate Cancer Trialists’ Collaborative Group. Maximum and rogen blockade in advanced prostate cancer: an overview of randomized trials[J]. Lancet, 2000; 355 (9214): 1 491-1498.
|
| 7. |
［5］Meyer F, Bairati I, Bedard C, Lacombe L, Tetu B, Fradet Y.Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer[J]. Urology, 2001; 58(2 Suppl 1): 71-77.
|
| 8. |
［6］Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F,Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C,Van Rensselaer S; Canadian Uro-Oncology Group.Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy:biochemical and pathological effects [J]. J Urol, 2001; 166(2): 500-506; discussion 506-507.
|
| 9. |
［7］Vallet BB. Radical perineal prostatectomy subsequent to bilateral orchiectomy[J]. Del Med J, 1944; 16:19.
|
| 10. |
［8］Monfette G, Dupont A, Labrie F, et al. Multiple advantages of prior and post-radical prostatectomy with combined endocrine therapy. Eur Urol, 1990, 18 (suppl 1): 97.
|
| 11. |
［9］Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer[J]. Eur Urol, 2000; 38(6): 706-713.
|
| 12. |
［10］Scolieri MJ, Altman A, R esnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated[J]? J Urol, 2000; 164(5): 1 465-1 472.
|
| 13. |
［11］Wood DP Jr, Beaman A, Banerjee M, Powell I, Pontes E,Cher ML. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy [ J ]. Clin Cancer Res, 1998;4(9): 2 119-2 123.
|
| 14. |
［12］Ohori M, Abbas F, Wheeler TM, Kattan MW, Scardino PT,Lerner SP. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology[J]. J Urol, 1999; 161(2): 500-504.
|
| 15. |
［13］Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period[J]. J Urol, 1999; 161(1): 163-168.
|
1/5
微信公眾號